Relaxin fusion polypeptides and uses thereof

US9382305B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Andreas Wilmen · Neunburg vorm Wald, DE
• Ulrich Haupts · Halle (Saale), DE
• Christoph Freiberg · Wuppertal, DE
• Mark Trautwein · Whippany, US
• Lars Linden · Mülheim an der Ruhr, DE
• Kirsten LEINEWEBER · Neviges, DE
• Hanna Tinel · Wuppertal, DE

Key dates

• Filing date: Jun 29, 2012
• Grant date: Jul 5, 2016
• Expiry date: Jul 15, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/75
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides Relaxin fusion polypeptides A-L-B with a non-wild type array of the Relaxin A-chain and Relaxin B-chain, wherein the A- and B-chains are connected by a linker peptide. The invention further provides Relaxin fusion polypeptides with extended half-life. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, pharmaceutical compositions and medical use of such fusion polypeptides.